Missed TIPPA 2018? Read our meeting report to get up to speed!
Missed ISMPP EU 2018? Hannah Mace provides a summary of the meeting’s poster presentations.
Missed ISMPP EU 2018? Duncan Campbell provides a summary of day 2 of the meeting.
From February, Nature journals will ask authors to disclose possible non-financial conflicts of interest, in a bid to further increase transparency in the publication of scientific work.
Themed From Publication to Practice: Advancing Science Through Effective Communication, this year’s Annual Meeting will feature enlightening sessions and peer-to-peer discussion of interest to both seasoned publication professionals and … Continue Reading Interested in the Latest Trends in Medical Publications? Attend the 14th Annual Meeting of ISMPP!
Missed ISMPP EU 2018? Read our meeting report to get up to speed!
Get up to speed with the latest ICMJE reporting guidelines update, including data sharing requirements and guidance on predatory and pseudo-journals.
Transparency of data from pharmaceutical industry-sponsored clinical trials has reached record levels. A recent study has shown that 93% of all such trials, relating to medicines approved by the European … Continue Reading Clinical trial data transparency reaches record levels
Online Registration Until January 3, 2018! Medical publication professionals from the pharmaceutical industry, medical communication agencies, journals, academia, etc., are all welcome to participate in the 2018 European Meeting of … Continue Reading Calling All Medical Publication Professionals – Join Us at the 2018 European ISMPP Meeting
Although most scientists understand the importance of publishing all study data, it remains a fact that articles describing data that do not confirm the author’s hypothesis are less likely to … Continue Reading Celebrating the positives in negative results
Three steps to transparency in clinical research: a new white paper from the Collaboration for Research Integrity and Transparency
Integrity and transparency are paramount to the accuracy, accessibility and credibility of medical research. Given that clinical evidence informs market approval of medical products, missing or inaccurate clinical trial data … Continue Reading Three steps to transparency in clinical research: a new white paper from the Collaboration for Research Integrity and Transparency
Recently, F1000Research published the first article of their new Registered Report initiative. The publisher is the first to go a step further with this publication format, combining the Registered Report … Continue Reading Registered Reports: enhancing transparency and reproducibility in scientific publication
BMC Research Notes has launched a new article type in the form of data notes, as introduced by the journal’s editor, Dirk Krüger, in a recent blog. Data notes are … Continue Reading Data notes: a new initiative to improve data visibility
Sponsors of clinical trials are required to provide result summaries in a format that is understandable to laypersons, as outlined in the EU Clinical Trials Regulation 536/2014 (Article 37) (EU … Continue Reading Guidance and important steps to consider when writing lay summaries
In 2007, the US Food and Drug Administration (FDA) issued the US FDA Amendments Act (FDAAA), in which it stated that all clinical trials of FDA-regulated products must be … Continue Reading Has the FDA Amendments Act improved clinical trial registration and publication?
In a new paper published in the BMJ, Ben Goldacre and co-workers suggest that pharmaceutical companies have variable policies on the reporting of clinical trials. While some have clear procedures … Continue Reading Audit of pharma policies on the reporting of data from clinical trials